Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2018 (2018), Article ID 1984718, 15 pages
https://doi.org/10.1155/2018/1984718
Review Article

The Potential of Angiogenin as a Serum Biomarker for Diseases: Systematic Review and Meta-Analysis

1Institute of Environmental Health, School of Public Health, Zhejiang University, Hangzhou 310058, China
2Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou 310058, China
3Program in Molecular and Cellular Biology, Zhejiang University, Hangzhou 310058, China
4Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China

Correspondence should be addressed to Jinghao Sheng; nc.ude.ujz@gnehshj and Zhengping Xu; nc.ude.ujz@uxpz

Received 15 October 2017; Revised 2 January 2018; Accepted 11 January 2018; Published 15 March 2018

Academic Editor: Benoit Dugue

Copyright © 2018 Dongdong Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Tsuji, Y. Sun, K. Kishimoto et al., “Angiogenin is translocated to the nucleus of HeLa cells and is involved in ribosomal RNA transcription and cell proliferation,” Cancer Research, vol. 65, no. 4, pp. 1352–1360, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Kieran, J. Sebastia, M. J. Greenway et al., “Control of motoneuron survival by angiogenin,” The Journal of Neuroscience, vol. 28, no. 52, pp. 14056–14061, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. I. E. Koutroubakis, C. Xidakis, K. Karmiris, A. Sfiridaki, E. Kandidaki, and E. A. Kouroumalis, “Serum angiogenin in inflammatory bowel disease,” Digestive Diseases and Sciences, vol. 49, no. 11-12, pp. 1758–1762, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. L. V. Hooper, T. S. Stappenbeck, C. V. Hong, and J. I. Gordon, “Angiogenins: a new class of microbicidal proteins involved in innate immunity,” Nature Immunology, vol. 4, no. 3, pp. 269–273, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. H. S. Lee, I. S. Lee, T. C. Kang, G.-B. Jeong, and S.-I. Chang, “Angiogenin is involved in morphological changes and angiogenesis in the ovary,” Biochemical and Biophysical Research Communications, vol. 257, no. 1, pp. 182–186, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. T. V. King and B. L. Vallee, “Neovascularisation of the meniscus with angiogenin. An experimental study in rabbits,” The Bone & Joint Journal, vol. 73, no. 4, pp. 587–590, 1991. View at Google Scholar
  7. K. A. Goncalves, L. Silberstein, S. Li et al., “Angiogenin promotes hematopoietic regeneration by dichotomously regulating quiescence of stem and progenitor cells,” Cell, vol. 166, no. 4, pp. 894–906, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Sheng and Z. Xu, “Three decades of research on angiogenin: a review and perspective,” Acta Biochimica et Biophysica Sinica, vol. 48, no. 5, pp. 399–410, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Shapiro, D. J. Strydom, K. A. Olson, and B. L. Vallee, “Isolation of angiogenin from normal human plasma,” Biochemistry, vol. 26, no. 16, pp. 5141–5146, 1987. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Blaser, S. Triebel, C. Kopp, and H. Tschesche, “A highly sensitive immunoenzymometric assay for the determination of angiogenin,” Clinical Chemistry and Laboratory Medicine, vol. 31, no. 8, pp. 513–516, 1993. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Montero, C. Guzmán, H. Cortés-Funes, and R. Colomer, “Angiogenin expression and prognosis in primary breast carcinoma,” Clinical Cancer Research, vol. 4, no. 9, pp. 2161–2168, 1998. View at Google Scholar
  12. D. Duranyildiz, H. Camlica, H. O. Soydinc, D. Derin, and V. Yasasever, “Serum levels of angiogenic factors in early breast cancer remain close to normal,” The Breast, vol. 18, no. 1, pp. 26–29, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. H. C. Chung, S. Y. Rha, J. B. Ahn et al., “Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer,” International Journal of Molecular Medicine, vol. 2, no. 4, pp. 465–470, 1998. View at Publisher · View at Google Scholar
  14. S. M. Sheen-Chen, H. L. Eng, W. J. Chen, F. F. Chou, and H. S. Chen, “Serum level of angiogenin in breast cancer,” Anticancer Research, vol. 20, no. 6C, pp. 4769–4771, 2000. View at Google Scholar
  15. S. Cronin, M. J. Greenway, S. Ennis et al., “Elevated serum angiogenin levels in ALS,” Neurology, vol. 67, no. 10, pp. 1833–1836, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. van Es, J. H. Veldink, H. J. Schelhaas et al., “Serum angiogenin levels are elevated in ALS, but not Parkinson’s disease,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 85, no. 12, pp. 1439-1440, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. R. L. McLaughlin, J. Phukan, W. McCormack et al., “Angiogenin levels and ANG genotypes: dysregulation in amyotrophic lateral sclerosis,” PLoS One, vol. 5, no. 11, article e15402, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. J. J. Deeks, D. G. Altman, and M. J. Bradburn, “Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis,” in Systematic Reviews in Health Care: Meta-Analysis in Context, M. Egger, G. D. Smith, and D. G. Altman, Eds., pp. 285–312, BMJ Publishing Group, London, UK, 2nd edition, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Piven, Y. A. Manaf, and M. A. Abdullah, “Context and implications of blood angiogenin level findings in healthy and breast cancer females of Malaysia,” 5th Kuala Lumpur International Conference on Biomedical Engineering 2011. IFMBE Proceedings, N. A. A. Osman, W. A. B. W. Abas, A. K. A. Wahab, and H. N. Ting, Eds., vol. 35, Springer, Berlin, Heidelberg, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. P. C. Bennett, P. S. Gill, S. Silverman, A. D. Blann, B. Balakrishnan, and G. Y. Lip, “Ethnic/racial differences in circulating markers of angiogenesis and their association with cardiovascular risk factors and cardiovascular disease,” International Journal of Cardiology, vol. 167, no. 4, pp. 1247–1250, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Pantsulaia, S. Trofimov, E. Kobyliansky, and G. Livshits, “Genetic and environmental determinants of circulating levels of angiogenin in community-based sample,” Clinical Endocrinology, vol. 64, no. 3, pp. 271–279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. J. V. Silha, M. Krsek, V. Hana et al., “The effects of growth hormone status on circulating levels of vascular growth factors,” Clinical Endocrinology, vol. 63, no. 1, pp. 79–86, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. K. N. Aronis, K. N. Diakopoulos, C. G. Fiorenza, J. P. Chamberland, and C. S. Mantzoros, “Leptin administered in physiological or pharmacological doses does not regulate circulating angiogenesis factors in humans,” Diabetologia, vol. 54, no. 9, pp. 2358–2367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Malamitsi-Puchner, J. Tziotis, A. Tsonou, A. Sarandakou, C. S. Bartsocas, and G. Creatsas, “Serum angiogenin levels in the female from birth to postmenopause,” Growth Factors, vol. 17, no. 1, pp. 75–79, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. Ø. Bruserud, F. Grovan, R. Lindås, C. Blymke Møinichen, and K. K. Østerhus, “Serum levels of angioregulatory mediators in healthy individuals depend on age and physical activity: studies of angiogenin, basic fibroblast growth factor, leptin and endostatin,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 65, no. 6, pp. 505–512, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. J. W. Fett, D. J. Strydom, R. R. Lobb et al., “Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells,” Biochemistry, vol. 24, no. 20, pp. 5480–5486, 1985. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Shimoyama, K. Yamasaki, M. Kawahara, and M. Kaminishi, “Increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression,” Clinical Cancer Research, vol. 5, no. 5, pp. 1125–1130, 1999. View at Google Scholar
  28. S. K. Ramcharan, G. Y. Lip, P. S. Stonelake, and A. D. Blann, “Angiogenin outperforms VEGF, EPCs and CECs in predicting Dukes’ and AJCC stage in colorectal cancer,” European Journal of Clinical Investigation, vol. 43, no. 8, pp. 801–808, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Brunner, E. Gunsilius, P. Schumacher, H. Zwierzina, G. Gastl, and R. Stauder, “Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia,” Journal of Hematotherapy & Stem Cell Research, vol. 11, no. 1, pp. 119–125, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Glenjen, K. A. Mosevoll, and Ø. Bruserud, “Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia,” International Journal of Cancer, vol. 101, no. 1, pp. 86–94, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. J. G. Kim, S. K. Sohn, D. H. Kim et al., “Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia,” Leukemia & Lymphoma, vol. 46, no. 6, pp. 885–891, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. M. A. Ismail, D. S. Eissa, and N. M. Heiba, “Cellular vascular endothelial growth factor and serum angiogenin in acute myeloid leukemia (clinical and prognostic significance),” Egyptian Journal of Haematology, vol. 38, pp. 41–46, 2013. View at Google Scholar
  33. C. A. Akkok, T. Hervig, S. Stamnesfet et al., “Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma,” Cytotherapy, vol. 13, no. 10, pp. 1259–1268, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. M. G. Alexandrakis, F. H. Passam, K. Sfiridaki et al., “Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival,” Leukemia Research, vol. 28, no. 3, pp. 259–266, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Gkotzamanidou, D. Christoulas, V. L. Souliotis, A. Papatheodorou, M. A. Dimopoulos, and E. Terpos, “Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma,” Medical Science Monitor, vol. 19, pp. 1188–1194, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Kastritis, M. Roussou, M. Michael et al., “High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients,” British Journal of Haematology, vol. 150, no. 5, pp. 587–591, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Terpos, K. Anargyrou, E. Katodritou et al., “Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents,” International Journal of Cancer, vol. 130, no. 3, pp. 735–742, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. M. G. Alexandrakis, F. H. Passam, C. A. Pappa et al., “Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes,” Leukemia Research, vol. 29, no. 1, pp. 41–46, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Hisai, J. Kato, M. Kobune et al., “Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity,” Clinical Cancer Research, vol. 9, no. 13, pp. 4852–4859, 2003. View at Google Scholar
  40. Y. Chao, C. Y. Wu, C. Y. Kuo et al., “Cytokines are associated with postembolization fever and survival in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization,” Hepatology International, vol. 7, no. 3, pp. 883–892, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Chao, C. P. Li, G. Y. Chau et al., “Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery,” Annals of Surgical Oncology, vol. 10, no. 4, pp. 355–362, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Wei, X. Gao, J. Du, J. Su, and Z. Xu, “Angiogenin enhances cell migration by regulating stress fiber assembly and focal adhesion dynamics,” PLoS One, vol. 6, no. 12, article e28797, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Sheng, W. Yu, X. Gao, Z. Xu, and G. F. Hu, “Angiogenin stimulates ribosomal RNA transcription by epigenetic activation of the ribosomal DNA promoter,” Journal of Cellular Physiology, vol. 229, no. 4, pp. 521–529, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. F. H. Passam, A. Sfiridaki, C. Pappa et al., “Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment,” International Journal of Laboratory Hematology, vol. 30, no. 1, pp. 17–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. E. N. Eldin, E. M. EI-Gezawy, M. W. Daoud et al., “Evaluation of serum level of some angiogenic factors in non Hodgkin’s lymphoma,” Basic Research Journal of Medicine and Clinical Sciences, vol. 1, no. 4, pp. 66–74, 2012. View at Google Scholar
  46. S. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold, “Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival,” Journal of Clinical Oncology, vol. 19, no. 2, pp. 577–583, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Tas, D. Duranyildiz, H. Oguz, H. Camlica, V. Yasasever, and E. Topuz, “Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients,” Melanoma Research, vol. 16, no. 5, pp. 405–411, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Tello-Montoliu, F. Marin, J. Patel et al., “Plasma angiogenin levels in acute coronary syndromes: implications for prognosis,” European Heart Journal, vol. 28, no. 24, pp. 3006–3011, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Lewicki, J. Siebert, N. Marek-Trzonkowska et al., “Elevated serum tryptase and endothelin in patients with ST segment elevation myocardial infarction: preliminary report,” Mediators of Inflammation, vol. 2015, Article ID 395173, 7 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. N. K. Idriss, G. Y. Lip, B. Balakrishnan, R. Jaumdally, C. J. Boos, and A. D. Blann, “Plasma haemoxygenase-1 in coronary artery disease. A comparison with angiogenin, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor,” Thrombosis and Haemostasis, vol. 104, no. 5, pp. 1029–1037, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Yu, M. Liu, X. Yang et al., “Diagnostic utility of ANG in coronary heart disease complicating chronic heart failure: a cross-sectional study,” Disease Markers, vol. 2016, Article ID 2740826, 6 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. J. V. Patel, M. Sosin, A. Gunarathne et al., “Elevated angiogenin levels in chronic heart failure,” Annals of Medicine, vol. 40, no. 6, pp. 474–479, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Jiang, L. Zhang, Y. Yu et al., “A pilot study of angiogenin in heart failure with preserved ejection fraction: a novel potential biomarker for diagnosis and prognosis?” Journal of Cellular and Molecular Medicine, vol. 18, no. 11, pp. 2189–2197, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. M. A. van Es, H. J. Schelhaas, P. W. van Vught et al., “Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis,” Annals of Neurology, vol. 70, no. 6, pp. 964–973, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. M. J. Greenway, M. D. Alexander, S. Ennis et al., “A novel candidate region for ALS on chromosome 14q11.2,” Neurology, vol. 63, no. 10, pp. 1936–1938, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Wu, W. Yu, H. Kishikawa et al., “Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis,” Annals of Neurology, vol. 62, no. 6, pp. 609–617, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. W. Qin, X. Jia, F. Wang et al., “Elevated plasma angiogenesis factors in Alzheimer’s disease,” Journal of Alzheimer's Disease, vol. 45, no. 1, pp. 245–252, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. N. Kim and H. Kim do, “Decreased serum angiogenin level in Alzheimer’s disease,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 38, no. 2, pp. 116–120, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Zorena, J. Mysliwska, M. Mysliwiec et al., “Modulatory factors responsible for neoangiogenesis in young patients with long-standing diabetes mellitus type 1,” Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, vol. 3, no. 2, pp. 144–149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Neubauer-Geryk, G. M. Kozera, B. Wolnik, S. Szczyrba, W. M. Nyka, and L. Bieniaszewski, “Angiogenin in middle-aged type 1 diabetes patients,” Microvascular Research, vol. 84, no. 3, pp. 387–389, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. N. Marek, K. Raczynska, J. Siebert et al., “Decreased angiogenin concentration in vitreous and serum in proliferative diabetic retinopathy,” Microvascular Research, vol. 82, no. 1, pp. 1–5, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Malamitsi-Puchner, A. Sarandakou, C. Dafogianni, J. Tziotis, and C. S. Bartsocas, “Serum angiogenin levels in children and adolescents with insulin-dependent diabetes mellitus,” Pediatric Research, vol. 43, no. 6, pp. 798–800, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Siebert, M. Reiwer-Gostomska, J. Mysliwska, N. Marek, K. Raczynska, and L. Glasner, “Glycemic control influences serum angiogenin concentrations in patients with type 2 diabetes,” Diabetes Care, vol. 33, no. 8, pp. 1829-1830, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. C. Gui, S. K. Li, Q. L. Nong, F. Du, L. G. Zhu, and Z. Y. Zeng, “Changes of serum angiogenic factors concentrations in patients with diabetes and unstable angina pectoris,” Cardiovascular Diabetology, vol. 12, no. 1, p. 34, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. N. F. Ahmed, S. Eissa, A. A. Ali et al., “Correlation of serum angiogenin level with various vascular complications in type 2 diabetic patients,” The Egyptian Journal Internal Medicine, vol. 24, pp. 63–71, 2012. View at Google Scholar
  66. R. Maier, M. Weger, E. M. Haller-Schober et al., “Application of multiplex cytometric bead array technology for the measurement of angiogenic factors in the vitreous,” Molecular Vision, vol. 12, pp. 1143–1147, 2006. View at Google Scholar
  67. M. Kolben, J. Blaser, K. Ulm et al., “Angiogenin plasma levels during pregnancy,” American Journal of Obstetrics and Gynecology, vol. 176, no. 1, pp. 37–41, 1997. View at Publisher · View at Google Scholar
  68. A. Malamitsi-Puchner, A. Sarandakou, G. Giannaki, D. Rizos, and I. Phocas, “Changes of angiogenin serum concentrations in the perinatal period,” Pediatric Research, vol. 41, no. 6, pp. 909–911, 1997. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Lassus, K. Teramo, I. Nupponen, H. Markkanen, K. Cederqvist, and S. Andersson, “Vascular endothelial growth factor and angiogenin levels during fetal development and in maternal diabetes,” Neonatology, vol. 84, no. 4, pp. 287–292, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. C. Yamashiro, Y. Ohnishi, K. Kanenishi, K. Hayashi, T. Yanagihara, and T. Hata, “Maternal and fetal circulating angiogenin levels in pregnancies with small-for-gestational-age and appropriate-for-gestational-age infants,” Gynecologic and Obstetric Investigation, vol. 49, no. 3, pp. 156–159, 2000. View at Publisher · View at Google Scholar · View at Scopus
  71. V. J. Karthikeyan, G. Y. Lip, S. Baghdadi, D. A. Lane, D. G. Beevers, and A. D. Blann, “Angiogenin and hemoxygenase in pregnancy: influence of hypertension,” Angiology, vol. 63, no. 3, pp. 194–198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Shaarawy, F. Al-Sokkary, M. Sheba, O. Wahba, H. O. Kandil, and I. Abdel-Mohsen, “Angiogenin and vascular endothelial growth factor in pregnancies complicated by preeclampsia,” International Journal of Gynaecology and Obstetrics, vol. 88, no. 2, pp. 112–117, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Reuvekamp, F. V. Velsing-Aarts, I. E. Poulina, J. J. Capello, and A. J. Duits, “Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 106, no. 10, pp. 1019–1022, 1999. View at Publisher · View at Google Scholar
  74. L. C. Kenny, M. A. Black, L. Poston et al., “Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study,” Hypertension, vol. 64, no. 3, pp. 644–652, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. V. Bourlev, N. Iljasova, L. Adamyan, A. Larsson, and M. Olovsson, “Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis,” Fertility and Sterility, vol. 94, no. 1, pp. 52–57, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. M. A. Aboulghar, R. T. Mansour, G. I. Serour, B. A. Elhelw, and M. Shaarawy, “Elevated concentrations of angiogenin in serum and ascitic fluid from patients with severe ovarian hyperstimulation syndrome,” Human Reproduction, vol. 13, no. 8, pp. 2068–2071, 1998. View at Publisher · View at Google Scholar · View at Scopus
  77. K. A. Oikonomou, A. N. Kapsoritakis, A. I. Kapsoritaki et al., “Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 17, no. 4, pp. 963–970, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Shimoyama, F. Gansauge, S. Gansauge, T. Oohara, M. K. and, and H. G. Beger, “Increased angiogenin expression in obstructive chronic pancreatitis surrounding pancreatic cancer but not in pure chronic pancreatitis,” Pancreas, vol. 18, no. 3, pp. 225–230, 1999. View at Publisher · View at Google Scholar · View at Scopus
  79. G. S. Bhatia, M. D. Sosin, J. V. Patel et al., “Plasma indices of angiogenesis in rheumatoid disease: relationship to cardiovascular risk factors and cardiac function,” International Journal of Cardiology, vol. 145, no. 3, pp. e105–e108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. T. Miyagaki, M. Sugaya, M. Kamata et al., “Serum angiogenin levels are decreased in patients with psoriasis,” Clinical and Experimental Dermatology, vol. 37, no. 7, pp. 792-793, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. T. Eleftheriadis, G. Antoniadi, V. Liakopoulos, G. Pissas, I. Stefanidis, and G. Galaktidou, “Plasma angiogenin and vascular endothelial growth factor a among hemodialysis patients,” Iranian Journal of Kidney Diseases, vol. 6, no. 3, pp. 209–215, 2012. View at Google Scholar
  82. E. Terpos, B. Asli, D. Christoulas et al., “Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome,” Haematologica, vol. 97, no. 11, pp. 1699–1703, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. D. F. Stroup, J. A. Berlin, S. C. Morton et al., “Meta-analysis of observational studies in epidemiology: a proposal for reporting,” JAMA, vol. 283, no. 15, pp. 2008–2012, 2000. View at Publisher · View at Google Scholar
  84. A. Stang, “Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses,” European Journal of Epidemiology, vol. 25, no. 9, pp. 603–605, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. X. Wan, W. Wang, J. Liu, and T. Tong, “Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range,” BMC Medical Research Methodology, vol. 14, no. 1, p. 135, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. J. L. Peters, A. J. Sutton, D. R. Jones, K. R. Abrams, and L. Rushton, “Comparison of two methods to detect publication bias in meta-analysis,” JAMA, vol. 295, no. 6, pp. 676–680, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. D. Jackson, I. R. White, and R. D. Riley, “Quantifying the impact of between-study heterogeneity in multivariate meta-analyses,” Statistics in Medicine, vol. 31, no. 29, pp. 3805–3820, 2012. View at Publisher · View at Google Scholar · View at Scopus
  88. R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986. View at Publisher · View at Google Scholar · View at Scopus
  89. J. G. Lijmer, P. M. Bossuyt, and S. H. Heisterkamp, “Exploring sources of heterogeneity in systematic reviews of diagnostic tests,” Statistics in Medicine, vol. 21, no. 11, pp. 1525–1537, 2002. View at Publisher · View at Google Scholar · View at Scopus
  90. C. A. Pappa, M. G. Alexandrakis, A. Boula et al., “Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients,” Hematological Oncology, vol. 31, no. 4, pp. 201–205, 2013. View at Publisher · View at Google Scholar · View at Scopus
  91. P. K. Goon, G. Y. Lip, P. S. Stonelake et al., “Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index,” Neoplasia, vol. 11, no. 8, pp. 771–779, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. C. Y. Spong, A. Ghidini, D. M. Sherer, J. C. Pezzullo, M. Ossandon, and G. S. Eglinton, “Angiogenin: a marker for preterm delivery in midtrimester amniotic fluid,” American Journal of Obstetrics and Gynecology, vol. 176, no. 2, pp. 415–418, 1997. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Skog, T. Wurdinger, S. van Rijn et al., “Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers,” Nature Cell Biology, vol. 10, no. 12, pp. 1470–1476, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. J. J. Beintema, J. Hofsteenge, M. Iwama et al., “Amino acid sequence of the nonsecretory ribonuclease of human urine,” Biochemistry, vol. 27, no. 12, pp. 4530–4538, 1988. View at Google Scholar
  95. J. Ilzecka, “Cerebrospinal fluid angiogenin level in patients with amyotrophic lateral sclerosis,” Acta Clinica Croat, vol. 47, no. 2, pp. 77–79, 2008. View at Google Scholar
  96. C. Moreau, P. Gosset, V. Brunaud-Danel et al., “CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients,” Amyotrophic Lateral Sclerosis, vol. 10, no. 3, pp. 175–181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. B. H. Yoon, S. Y. Oh, R. Romero et al., “An elevated amniotic fluid matrix metalloproteinase-8 level at the time of mid-trimester genetic amniocentesis is a risk factor for spontaneous preterm delivery,” American Journal of Obstetrics & Gynecology, vol. 185, no. 5, pp. 1162–1167, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. R. Madazli, A. Atiş, H. Uzun, and F. Aksu, “Mid-trimester amniotic fluid angiogenin, lactate dehydrogenase and fibronectin in the prediction of preterm delivery,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 106, no. 2, pp. 160–164, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. V. Urquidi, S. Goodison, J. Kim, M. Chang, Y. Dai, and C. J. Rosser, “Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection,” Urology, vol. 79, no. 5, pp. 1185.e1–1185.e6, 2012. View at Google Scholar
  100. V. Soukup, M. Kalousová, O. Capoun et al., “Panel of urinary diagnostic markers for non-invasive detection of primary and recurrent urothelial urinary bladder carcinoma,” Urologia Internationalis, vol. 95, no. 1, pp. 56–64, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. M. I. Shabayek, O. M. Sayed, H. A. Attaia, H. A. Awida, and H. Abozeed, “Diagnostic evaluation of urinary angiogenin (ANG) and clusterin (CLU) as biomarker for bladder cancer,” Pathology & Oncology Research, vol. 20, no. 4, pp. 859–866, 2014. View at Publisher · View at Google Scholar · View at Scopus
  102. C. J. Rosser, S. Ross, M. Chang et al., “Multiplex protein signature for the detection of bladder cancer in voided urine samples,” The Journal of Urology, vol. 190, no. 6, pp. 2257–2262, 2013. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Eissa, M. Swellam, R. A. Labib, T. El-Zayat, and O. El Ahmady, “A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot,” The Journal of Urology, vol. 181, no. 3, pp. 1353–1360, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Eissa, G. Kenawy, M. Swellam, A. A. El-Fadle, A. A. Abd El-Aal, and O. El-Ahmady, “Comparison of cytokeratin 20 RNA and angiogenin in voided urine samples as diagnostic tools for bladder carcinoma,” Clinical Biochemistry, vol. 37, no. 9, pp. 803–810, 2004. View at Publisher · View at Google Scholar · View at Scopus